EUZG.DE (EUZG.DE) News
Follow EUZG.DE (EUZG.DE) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 6 public stories across 1 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Eckert & Ziegler Brazil signs TerThera supply deal for GMP — grade terbium — 161 precursor
Eckert & Ziegler Brazil signed a strategic supply agreement with TerThera for GMP-compliant non-carrier-added terbium-161 precursor. Deal sets up a dedicated supply chain for Tb-161 in South America, targeting faster acc
NEWS | Oct 13, 2026, 12:11 PM UTC
L
Eckert & Ziegler signs Terbium — 161 supply deal with TerThera for Brazil unit
Eckert & Ziegler signed a strategic supply contract with TerThera for GMP-grade, carrier-free terbium-161 for Brazil. TerThera will supply Tb-161 to Eckert & Ziegler Brazil, strengthening the isotope supply chain in Sout
NEWS | Oct 13, 2026, 12:11 PM UTC
L
BRIEF — Eckert & Ziegler Brazil And Terthera Sign Supply Agreement For Terbium — 161
Oct 13 (Reuters) — ECKERT & ZIEGLER SE: Eckert & Ziegler Brazil And Terthera Sign Supply Agreement For Terbium-161 Source text:... Further company coverage: EUZG.DE (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com;
NEWS | Oct 13, 2026, 12:05 PM UTC
L
Eckert & Ziegler Brazil signs TerThera supply deal for GMP terbium — 161 precursor
Eckert & Ziegler Brazil signed a supply agreement with TerThera for GMP-compliant non-carrier-added terbium-161 precursor. Deal aims to establish a reliable South American supply chain for Tb-161 radioligand therapies, t
NEWS | Oct 13, 2026, 12:02 PM UTC
L
EQS — News: Eckert & Ziegler and TerThera Sign Supply Agreement to Bring Next — Generation GMP Terbium — 161 Radiopharmaceutical Therapies to Brazilian Patient
EQS-News: Eckert & Ziegler SE / Key word(s): Contract Eckert & Ziegler and TerThera Sign Supply Agreement to Bring Next-Generation GMP Terbium-161 Radiopharmaceutical Therapies to Brazilian Patient 13.10.2026 / 14:00 CET
EQUITY | Oct 13, 2026, 12:02 PM UTC
L
NuWays reiterates BUY on Eckert & Ziegler, sets EUR 21.50 price target
NuWays reiterated a BUY rating on Eckert & Ziegler, setting a 12-month target price of EUR 21.50. Report flags a valuation gap versus recent radiopharma M&A, citing implied multiples of 5.3x sales and 16x manufacturing E
EARNINGS | Oct 13, 2026, 07:01 AM UTC